Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.

Publication date: Jan 12, 2024

This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity, outcomes, and the efficacy of the antiviral agent Paxlovid (nirmatrelvir/ritonavir). MAFLD, affecting a quarter of the global population, emerges as a potential risk factor for severe COVID-19, yet the underlying pathophysiological mechanisms remain elusive. This study focuses on the clinical significance of Paxlovid, the first orally bioavailable antiviral agent granted Emergency Use Authorization in the United States. Notably, outcomes from phase II/III trials exhibit an 88% relative risk reduction in COVID-19-associated hospitalization or mortality among high-risk patients. Despite conflicting data on the association between MAFLD and COVID-19 severity, this research strives to bridge the gap by evaluating the effectiveness of Paxlovid in MAFLD patients with COVID-19, addressing the scarcity of relevant studies.

Open Access PDF

Concepts Keywords
Covid Antiviral Agents
Drugs Antiviral Agents
High COVID-19
Hospitalization COVID-19
Liver Drug Combinations
Drug Combinations
Prospective Studies


Type Source Name
disease MESH COVID-19
disease MESH Liver Disease
drug DRUGBANK Ritonavir
disease VO population
disease MESH clinical significance
disease MESH Emergency
disease VO Gap
disease VO effectiveness
disease MESH Fatty Liver
disease MESH infection
disease VO Severe acute respiratory syndrome coronavirus 2
disease MESH metabolic syndrome
disease MESH cytokine storm
drug DRUGBANK Coenzyme M
disease IDO symptom
disease VO time
disease MESH bacterial infections
disease MESH liver cirrhosis
disease MESH malignancies
disease MESH alcoholism
pathway KEGG Alcoholism
disease IDO blood
disease MESH overweight
disease MESH obesity
disease MESH diabetes mellitus
disease MESH abnormalities
disease MESH pneumonia
drug DRUGBANK Medical air
disease MESH tachypnea
disease VO protocol
drug DRUGBANK Acetaminophen
drug DRUGBANK Ibuprofen
drug DRUGBANK Ambroxol
drug DRUGBANK Enoxaparin
drug DRUGBANK Amoxicillin
drug DRUGBANK Clavulanic acid
drug DRUGBANK Azithromycin
drug DRUGBANK Clarithromycin
disease VO dose
drug DRUGBANK Dexamethasone
drug DRUGBANK Oxygen
drug DRUGBANK Prothrombin
drug DRUGBANK Fibrinogen Human
drug DRUGBANK L-Alanine
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Saquinavir
disease VO USA
disease MESH hypertension
disease MESH COPD
disease MESH heart disease
disease VO age
drug DRUGBANK L-Leucine
disease MESH Non-alcoholic Fatty Liver Disease
pathway KEGG Non-alcoholic fatty liver disease
drug DRUGBANK Proline

Original Article

(Visited 1 times, 1 visits today)